Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bahrain to screen children for genetic diseases:

This article was originally published in Clinica

Executive Summary

The Bahrain ministry of health has initiated a blood screening programme for school children. According to the programme, some 6,500 children from 38 government and private schools will be screened for genetic diseases. The hereditary anaemia society is to provide BD20,000 ($53,200) towards the project, reports the Bahrain Tribune. Dr Shaikha Al Arayyed, head of the national hereditary disease committee and consultant clinical geneticist at the ministry of health, said that if the tests were carried out in private laboratories they would cost at least BD25 each. She hoped that parents and donations from society would help to fund the project. Dr Al Arayyed said it would help the spread of genetic diseases such as sickle cell anaemia, with which some 100 babies are born each year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel